Jimmy Mengel recommended this company, I've been holding it for 6 plus months now with great returns. I'm still bullish on it, so are a number of analysts as per the followin.....
Needham analyst Matt McGinley maintained a Buy rating on Curaleaf Holdings (OTC:) on Tuesday, setting a price target of $18.5, which is approximately 18.94% above the present share price of $15.55.
McGinley expects Curaleaf Holdings to post earnings per share (EPS) of -$0.01 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Curaleaf Holdings, with an average price target of $16.99.
The analysts price targets range from a high of $20 to a low of $14.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $182.41 million and a net profit of $16.37 million. The company's market cap is $10.33 billion.
According to TipRanks.com, Needham analyst Matt McGinley is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 123.0% and a 88.57% success rate.
Curaleaf Holdings, Inc. is a life science company, which engages in owning and managing licensed cannabis businesses which cultivate, process and/or dispense cannabis and cannabis derived products. It operates through Cannabis Operations and Non-Cannabis Operations segments. The Cannabis Operations segment production and sale of cannabis via retail and wholesale channels. The Non-Cannabis Operations segment provides professional services including cultivation, processing and retail know-how, and back office administration, intellectual property licensing,real estate leasing services, and lending facilities to medical and adult-use cannabis licensee. The company was founded on November 13, 2014 and is headquartered in Vancouver, Canada.